Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL9345314 | 0.96 | ALDH1A1 (0.52) | ALDH1A1LMNAHSD17B10FAAHCA1 | |
| Ethyl Acetate SCHEMBL7564192 | 0.94 | ALDH1A1 (0.50) | ALDH1A1LMNAHSD17B10FAAHCA1 | |
| Acetic Acid Propyl Ester SCHEMBL4383055 | 0.93 | ALDH1A1 (0.52) | ALDH1A1LMNAHSD17B10FAAHCA1 | |
| Hexane SCHEMBL27527360 | 0.92 | ALDH1A1 (0.56) | ALDH1A1LMNAHSD17B10FAAHCA1 | |
| Hexane SCHEMBL27496679 | 0.92 | ALDH1A1 (0.56) | ALDH1A1LMNAHSD17B10FAAHCA1 | |
| Hexane SCHEMBL27497972 | 0.92 | ALDH1A1 (0.56) | ALDH1A1LMNAHSD17B10FAAHCA1 | |
| Hexane SCHEMBL27517529 | 0.89 | ALDH1A1 (0.52) | ALDH1A1LMNAHSD17B10FAAHCA1 | |
| Acetic Acid Isobutyl Ester SCHEMBL9039235 | 0.86 | ALDH1A1 (0.47) | ALDH1A1FAAHCA1ZDHHC7PTPN1 | |
| Hexane SCHEMBL27497622 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10FAAHCA1 | |
| Hexane SCHEMBL27496963 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10FAAHCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103134862-A | Quality detection method of pediatric compound paracetamol, atificial cow-bezoar and chlorphenamine maleate granules | SICHUAN KELUN PHARM RES CO LTD | 2013-06-05 | — | — | CN | claimed |
| CN-103134861-A | Quality detection method of compound paracetamol and chlorphenamine maleate granules | SICHUAN KELUN PHARM RES CO LTD | 2013-06-05 | — | — | CN | claimed |
| US-20230413886-A1 | MATERNAL SUPPLEMENT | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-12-28 | — | — | US | disclosed |
| US-11850238-B2 | Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy | POXEL (FR) | 2023-12-26 | — | — | US | disclosed |
| US-11701404-B2 | Human milk fortifier composition | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-07-18 | — | — | US | disclosed |
| US-11696595-B2 | Maternal supplement | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-07-11 | — | — | US | disclosed |
| US-20230112080-A1 | USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF ADRENOLEUKODYSTROPHY OR ADRENOMYELONEUROPATHY | POXEL (FR) | 2023-04-13 | — | — | US | disclosed |
| EP-4125886-A1 | USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF ADRENOLEUKODYSTROPHY OR ADRENOMYELONEUROPATHY | Poxel (FR) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335048-A | Use of thienopyridone derivatives for the treatment of adrenoleukodystrophy or adrenomyeloneuropathy | 博希尔公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20220054514-A1 | HUMAN MILK FORTIFIER COMPOSITION | NESTLE SA (CH) | 2022-02-24 | — | — | US | disclosed |
| EP-0198689-A2 | Pseudopterosin and synthetic derivatives thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1986-10-22 | — | — | EP | disclosed |
| US-4604388-A | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof in a method of counteracting histamine | A. H. ROBINS COMPANY, INCORPORATED (US) | 1986-08-05 | — | — | US | disclosed |
| US-4592866-A | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof | A. H. ROBINS COMPANY, INC. (US) | 1986-06-03 | — | — | US | disclosed |
| US-4511511-A | ANTIINFLAMMATORY AGENTS | CROZER-CHESTER MEDICAL CENTER (US) | 1985-04-16 | — | — | US | disclosed |
| EP-0126043-A1 | Carbohydrate derivatives and compositions thereof for therapeutic or diagnostic use | ANDERSSON, Bengt (SE) | 1984-11-21 | — | — | EP | disclosed |
| EP-0107930-A2 | Fused aromatic oxazepinones and sulphur analogues thereof and their preparation and use in counteracting histamine | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1984-05-09 | — | — | EP | disclosed |
| EP-0098252-A2 | New and novel glycosides, glycoconjugates and processes for their preparation | BIOCARB AB (SE) | 1984-01-11 | — | — | EP | disclosed |
| US-4279822-A | ANTIEMETICS | A. H. ROBINS COMPANY, INC. (US) | 1981-07-21 | — | — | US | disclosed |
| US-RE28973-E | PARKINSON'S DISEASE | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850238-B2 | Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy | NAT1, SLC19A2, TPMT | ALDH1A1 71/4885LMNA 2546/4885HSD17B10 135/4885 |
| US-20230112080-A1 | USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF ADRENOLEUKODYSTROPHY OR ADRENOMYELONEUROPATHY | NAT1, SLC19A2, TPMT | ALDH1A1 71/4885LMNA 2546/4885HSD17B10 135/4885 |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | ALDH1A1 901/4885LMNA 2938/4885HSD17B10 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.